• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

FDA-TRACK

The list below provides information on FDA’s performance measures and projects as aligned to FDA strategic priorities and program offices. This list enables you to view charts of performance data and progress on important projects and programs.

To view completed FDA-TRACK performance measures and projects view the Archive Index

Filter








Results

Number of results: 20

ItemProgramOfficeStrategic PlanStrategic Goal/Area
1Number of guidances and regulations issuedOSMPOffice of Special Medical ProgramsN/AN/A
2Percentage of RFD decisions issued in the month reviewed within 60 daysOSMPOffice of Combination ProductsN/AN/A
3Total number of RFDs filed by OCP in the monthOSMPOffice of Combination ProductsN/AN/A
4Total number of orphan drug designation reviews completed in the monthOSMPOffice of Orphan Products DevelopmentN/AN/A
5Percentage of orphan drug designation reviews completed in 90 days or lessOSMPOffice of Orphan Products DevelopmentN/AN/A
6Total number of orphan drug designation decisions that resulted in orphan designation in the monthOSMPOffice of Orphan Products DevelopmentN/AN/A
7Total number of orphan drug approvals in the monthOSMPOffice of Orphan Products DevelopmentN/AN/A
8Total number of HUD designation reviews completed in the monthOSMPOffice of Orphan Products DevelopmentN/AN/A
9Percentage of HUD designation reviews completed in 45 days or lessOSMPOffice of Orphan Products DevelopmentN/AN/A
10Total number of HUD decisions that resulted in HUD designation in the monthOSMPOffice of Orphan Products DevelopmentN/AN/A
11Cumulative number of pediatric devices that have been provided assistance by the Pediatric Device ConsortiaOSMPOffice of Orphan Products DevelopmentN/AN/A
12Number of internal safety meetings for pediatric products or issues in the monthOSMPOffice of Pediatric TherapeuticsN/AN/A
13Number of product safety assessment meetings coordinated for public review in the monthOSMPOffice of Pediatric TherapeuticsN/AN/A
14Number of medical products studied in children with pediatric safety labeling changes in the monthOSMPOffice of Pediatric TherapeuticsN/AN/A
15Number of Pediatric Advisory Committee (PAC) related activities in the monthOSMPOffice of Pediatric TherapeuticsN/AN/A
16Number of contacts with foreign regulators to discuss scientific, ethical or safety issues related to pediatrics in the monthOSMPOffice of Pediatric TherapeuticsN/AN/A
17Number of contacts with the Pediatric Review Committee (PeRC), the review divisions, and other FDA colleagues to provide Pediatric Investigation Plan (PIP) information to inform internal discussionsOSMPOffice of Pediatric TherapeuticsN/AN/A
18Number of presentations/participation at U.S. conferences, stakeholder meetings, and trainings during the monthOSMPOffice of Pediatric TherapeuticsN/AN/A
19Number of international outreach efforts during the monthOSMPOffice of Pediatric TherapeuticsN/AN/A
20Number of publicationsOSMPOffice of Pediatric TherapeuticsN/AN/A

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information in the Archive Index may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.